KRAS SMALL MOLECULE INHIBITORS

Claims

The compounds of formulas (I)–(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma protein (KRAS) and are expected to be useful as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions comprising compounds of formulas (I)–(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for using the compounds or their pharmaceutically acceptable salts in cancer therapy and prophylaxis and for preparing pharmaceutical products for this purpose. A compound selected from the group consists of the compounds of formulas (III), (IV), (VI), and (VII), or a pharmaceutically acceptable salt thereof.